Despite boasting a $1.5 billion sales beat, Eli Lilly’s earnings were overshadowed by its top competitor Novo Nordisk's efforts to usurp Pfizer in a bidding war over clinical-stage obesity biotech Metsera.
Responding to questions from ...
↧